Almost five million lives could be saved annually if low- and middle-income countries (LMICs) invested 1% more of GDP in public healthcare spending – and used at least 40% of this to prevent and treat non-communicable diseases (NCDs). This is according to Airfinity research commissioned by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), […] Continue reading ->
GENEVA – Cardiometabolic diseases, a group of non-communicable diseases (NCDs) including cardiovascular disease, stroke, diabetes, and non-alcoholic fatty liver disease, are on the rise globally, threatening life expectancy gains and burdening vulnerable economies with excess healthcare costs. These diseases already contribute to over 30% of global deaths each year. With one billion people now living […] Continue reading ->
GENEVA – Partnerships between industry, multilateral organizations, and other stakeholders are essential to overcoming challenges and improving access to innovations. This was the key message at an International Federation of Pharmaceutical Manufacturers (IFPMA) event on Tuesday evening, held on the sidelines of the World Health Assembly in Geneva. The gathering brought together representatives from the […] Continue reading ->
Amidst the anticipated increase in vaccine-preventable diseases as the global population ages, a first-of-its-kind study has underscored the dual benefits of adult immunization programs. Beyond saving lives and preventing severe illnesses, the study found these programs offer substantial financial advantages to nations by reducing the need for costly hospitalizations and emergency medical interventions and avoiding […] Continue reading ->
A new Health Technology Access Pool (H-TAP), which aims to broaden the scope of IP and patent-sharing with low- and middle-income countries and a new African Union co-sponsored ‘manufacturing support platform’ were among the initiatives announced this week at the Second World Local Production forum in The Hague. The global forum, the second ever to […] Continue reading ->
One of the most intense debates in the pandemic accord negotiations is over how to fast-track the development and equitable rollout of vaccines and medicines, with pharmaceutical companies insisting that any infringement on intellectual property (IP) rights will stifle innovation and that voluntary arrangements are the way forward. A recent event to showcase voluntary licensing […] Continue reading ->
Regional vaccine production features in the draft pandemic accord, but there is still a long road before this becomes a reality Aspen Pharmacare invested millions of dollars in scaling up its South African production plant to make COVID-19 vaccines – yet it never sold a single vial. Meanwhile, in a “demoralising blow”, Bangladesh’s government rejected […] Continue reading ->
CEOs from the world’s largest pharmaceutical companies issued a call to G7 leaders on Friday to oppose the inclusion of intellectual property rights waivers and pathogen benefit sharing in the World Health Organization’s (WHO) pandemic treaty.  In meetings with Japanese Prime Minister and chair of next month’s G7 summit Fumio Kishida this week, a delegation […] Continue reading ->